Related Experiment Video
Updated: Jun 20, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
Chenyang Jiang1,2, Hao Sun3, Zhongxing Jiang1
1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in Oncology
|July 23, 2024
Summary
Recent clinical trial setbacks for CD47-SIRPα-targeted therapies, including Magrolimab and Evorpacept in myelodysplastic syndromes, raise concerns about their development feasibility. This review examines challenges and proposes solutions for advancing CD47-SIRPα drug development.
Area of Science:
- Immunology
- Oncology
- Drug Development
Background:
- CD47, an innate immune checkpoint, emerged as a promising therapeutic target, likened to PD-1.
- Early clinical development and industry investments fueled optimism for CD47-targeted therapies.
Purpose of the Study:
- To review the challenges in developing CD47-SIRPα-targeted drugs.
- To analyze factors contributing to recent clinical trial setbacks.
- To discuss future perspectives and solutions for CD47-SIRPα drug development.
Main Methods:
- Literature review of CD47-SIRPα drug development.
- Analysis of recent clinical trial outcomes (Magrolimab, Evorpacept).
- Discussion of industry trends and investment landscape.
Main Results:
- Recent Phase 3 (ENHANCE) and Phase 2 (ASPEN-02) trials for CD47-targeted therapies in myelodysplastic syndromes (MDS) reported failures.
- These setbacks have introduced significant doubt regarding the clinical utility of targeting CD47 in oncology.
- The efficacy of CD47-SIRPα blockade as a monotherapy or in combination requires further investigation.
Conclusions:
- Developing CD47-SIRPα-targeted drugs faces significant hurdles.
- Understanding the complex tumor microenvironment and immune evasion mechanisms is crucial.
- Future strategies may involve combination therapies, novel target identification, or refined patient selection to overcome current challenges.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K